dr.

(Saskia) S de Groot

Profile

Saskia de Groot completed the bachelor programme Health Policy & Management at the Erasmus University Rotterdam in 2007. In 2009, she obtained her master’s degree in Health Economics, Policy & Law. She continued her studies by enrolling in a research master programme in Health Sciences with a specialisation in Clinical Epidemiology at the Netherlands Institute for Health Sciences (2009–2011).

During her studies at the Erasmus University Rotterdam, she started working as a research assistant at the institute of Health Policy & Management. After obtaining her master's degree, she started working on a PhD project on the evaluation of clinical and economic outcomes of new therapies for metastatic renal cell carcinoma at the same institute. She finished her PhD thesis in 2016. Besides her research on conditional funding of expensive inpatient drugs, she worked on various advisory projects, including different projects for the Dutch National Health Care Institute.

• All publications (19)

  • Article (17)

    • V.J. Wester, S. de Groot, T.A. Kanters, L. Wagner, J. Ardesch, I. Corro Ramos, M.J. Enders-Slegers, M. de Ruiter, S. le Cessie, J. Los, G. Papageorgiou, N.J.A. van Exel & M.M. Versteegh (2020). Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE). FRONTIERS IN NEUROLOGY, 11 (3). doi: 10.3389/fneur.2020.00003 [go to publisher's site]
    • B. Grigore, O. Ciani, F. Dams, C. Federici, S. de Groot, M. Möllenkamp, S. Rabbe, K. Shatrov, A. Zemplenyi & R. Taylor (2020). Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines. Pharmacoeconomics (Print), 38, 1055-1070. doi: 10.1007/s40273-020-00935-1
    • S. de Groot, C.F. Enters-Weijnen, P.H. Geelhoed-Duijvestijn & T.A. Kanters (2018). A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. BMJ Open, 8 (3). doi: 10.1136/bmjopen-2017-019864 [go to publisher's site]
    • N.C. Buyukkaramikli, S. de Groot, R. Riemsma, D. Fayter, N. Armstrong, P. Portegijs, S. Duffy, J. Kleijnen & M.J. Al (2018). Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0708-4
    • S. de Groot, W.K. Redekop, M.M. Versteegh, S. Sleijfer, E. Oosterwijk, L.A.L.M. Kiemeney & C.A. Uyl - de Groot (2018). Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Quality of Life Research, 27, 115-124. doi: 10.1007/s11136-017-1704-4
    • S.G.R. Verelst, H.M. Blommestein, S. de Groot, S. Gonzalez-McQuire, L. DeCosta, J.B. de Raad, C.A. de Uyl-de Groot & P. Sonneveld (2018). Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). HemaSphere, 2 (4). doi: 10.1097/HS9.0000000000000045
    • N.C. Büyükkaramikli, S. de Groot, D. Fayter, R. Wolff, N. Armstrong, L. Stirk, G. Worthy, F.G. Albuquerque de Almeida, J. Kleijnen & M.J. Al (2017). Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. Pharmacoeconomics (Print). doi: 10.1007/s40273-017-0581-6
    • S. de Groot, H.M. Blommestein, W.K. Redekop, S. Sleijfer, L. Kiemeney, E. Oosterwijk & C.A. de Uyl-de Groot (2017). Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. PLoS One (print), 12 (5):e0177364. doi: 10.1371/journal.pone.0177364
    • S. de Groot, W.K. Redekop, S. Sleijfer, E. Oosterwijk, A. Bex, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2016). Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry. Urology, 95, 121-127. doi: 10.1016/j.urology.2016.04.042
    • S. de Groot, S. Sleijfer, W.K. Redekop, E. Oosterwijk, J. Haanen, L.A.L.M. Kiemeney & C.A. de Uyl-de Groot (2016). Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. Bmc Cancer, 16, 364. doi: 10.1186/s12885-016-2395-x
    • H.M. Blommestein, S. de Groot, M. Aarts, P. Vemer, R. de Vries, A.F.M. Abeelen, E.F.M. Posthuma & C.A. de Uyl-de Groot (2016). Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. Leukemia Research, 50, 37-45. doi: 10.1016/j.leukres.2016.09.005
    • S. de Groot, N. van der Linden, M.G. Franken, H.M. Blommestein, B. Leeneman, E.M. van Rooijen, J.J.M. van der Hoeven, M. Wouters, H.M. Westgeest & C.A. de Uyl-de Groot (2016). Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value in Health. doi: 10.1016/j.jval.2016.02.007
    • H.M. Blommestein, S.G.R. Verelst, S. de Groot, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2015). A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. European Journal of Haematology, 96 (2), 198-208. doi: 10.1111/ejh.12571
    • C.W.M. van Gils, S. de Groot, S.S. Tan, W.K. Redekop, M. Koopman, C. Punt & C.A. de Uyl-de Groot (2015). Real-world resource use and costs of adjuvant treatment for stage III colon cancer. European Journal of Cancer Care, 24 (3), 321-332. doi: 10.1111/ecc.12154
    • S. de Groot, A.J. Rijnsburger, M.M. Versteegh, J.M. Heymans, S. Kleijnen, W.K. Redekop & I. Verstijnen (2015). Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers. BMJ Open, 5::e007241. doi: 10.1136/bmjopen-2014-007241
    • C.W.M. van Gils, S. de Groot, W.K. Redekop, M. Koopman, C.J.A. Punt & C.A. de Uyl-de Groot (2013). Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence. Pharmacoeconomics (Print), 31 (8), 703-718. doi: 10.1007/s40273-013-0061-6
    • C.A. de Uyl-de Groot, S. de Groot & A. Steenhoek (2010). The economics of improved cancer survival rates: better outcomes, higher costs. Expert review of pharmacoeconomics & outcomes research, 10 (3), 283-292. doi: 10.1586/erp.10.27

  • Report (1)

    • G. de Graaf, S. de Groot, V.J. Wester, H.E. Vellekoop, M.M. Versteegh & M. Rutten-van Molken (2019). WAARDEBEPALING, IMPLEMENTATIE EN BEKOSTIGING VAN VOORSPELLENDE TESTEN IN NEDERLAND. (Extern rapport). : ZonMW [go to publisher's site]

  • Doctoral thesis (1)

    • S. de Groot. Evidence from clinical practice to support healthcare decision making, evaluation of clinical and economic outcomes of new therapies for metastatic renal cell carcinoma. EUR Prom./coprom.: prof.dr. C.A. de Uyl-de Groot, L.A.L.M. Kiemeney & dr. W.K. Redekop.

• Present position

  (external) researcher

  University

  Erasmus University Rotterdam

  School

  Erasmus School of Health Policy & Management

  Department

  Health Technology Assessment (HTA)

  Country

  The Netherlands